{
    "nct_id": "NCT05438303",
    "official_title": "A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran Etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers",
    "inclusion_criteria": "* Healthy postmenopausal female participants aged 50 to 70 years with suitable veins for cannulation or repeated venipuncture.\n* Participants must be postmenopausal by fulfilling the following criterion:\n* Have a Body mass index (BMI) between 19 and 35 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive as measured at screening.\n* Must agree to not use warfarin or phenytoin (and other coumarin-derived vitamin K antagonist anticoagulants) during study, and for 2 weeks after last administration of IMP.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 50 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* History of any clinically significant disease or disorder as described by the Investigator.\n* History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.\n* Use of systemic estrogen-containing hormone replacement therapy within 6 months prior to first dose in the study.\n* Have taken any proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, pantoprazole, etc.) within 14 days of beginning study treatment (ie, first administration of omeprazole in Arm A.\n* Have taken any drug with enzyme-inducing properties such as St John's Wort within 3 weeks of screening.\n* Presence of any contraindication to the probe substrates omeprazole, midazolam, dabigatran or celecoxib per the United States Package Insert.\n* Any of the following signs or confirmation of COVID-19 infection:\n* Subject has a positive RT-PCR test for SARS-CoV-2 prior to randomization.\n* Clinical signs and symptoms consistent with COVID-19 (eg, fever, dry cough, dyspnea, sore throat, fatigue) or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or at randomization.\n* Subject has been previously hospitalized with COVID-19 infection within the last 12 months.",
    "miscellaneous_criteria": ""
}